Initiation of aripiprazole once-monthly in patients with schizophrenia

References

• DeLisi LE. The concept of progressive brain change in schizophrenia: implications for understanding schizophrenia. Schizophr Bull 2008;34:312-21
   PubMed Web of Science ®Google Scholar
• Modestin J, Huber A, Satirli E, et al. Long-term course of schizophrenic illness: Bleuler's study reconsidered. Am J Psychiatry 2003;160:2202-8
   PubMed Web of Science ®Google Scholar
• van Os J, Kapur S. Schizophrenia. Lancet 2009;374:635-45
   PubMed Web of Science ®Google Scholar
• Emsley R, Chiliza B, Asmal L. The evidence for illness progression after relapse in schizophrenia. Schizophr Res 2013;148:117-21
   PubMed Web of Science ®Google Scholar
• Zipursky RB, Menezes NM, Streiner DL. Risk of symptom recurrence with medication discontinuation in first-episode psychosis: a systematic review. Schizophr Res 2014;152:408-14
   PubMed Web of Science ®Google Scholar
• Dibonaventura M, Gabriel S, Dupclay L, et al. A patient perspective of the impact of medication side effects on adherence: results of a cross-sectional nationwide survey of patients with schizophrenia. BMC Psychiatry 2012;12:20
   PubMed Web of Science ®Google Scholar
• Hasan A, Falkai P, Wobrock T, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry 2013;14:2-44
   PubMed Web of Science ®Google Scholar
• Offord S, Lin J, Mirski D, Wong B. Impact of early nonadherence to oral antipsychotics on clinical and economic outcomes among patients with schizophrenia. Adv Ther 2013;30:286-97
   PubMed Web of Science ®Google Scholar
• Abilify Maintena US (aripiprazole). Full Prescribing Information, Otsuka Pharmaceutical Co. Ltd, Tokyo, Japan. Available at: http://www.otsuka-us.com/Products/Documents/Abilify.M.PI.pdf. Accessed January 21, 2015
   Google Scholar
• Abilify Maintena EU (aripiprazole). Full Prescribing Information, Otsuka Pharmaceutical Europe Ltd, Wexham, UK. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000471/WC500020170.pdf. [Last accessed January 21, 2015]
   Google Scholar
• Abilify Maintena CAN (aripiprazole). Full Prescribing Information, Otsuka Canada Pharmaceutical Inc., Saint-Laurent, QC, Canada. Available at: webprod5.hc-sc.gc.ca/dpd-bdpp/item-iteme.do?pm-mp=00020719. [Last accessed January 21, 2015]
   Google Scholar
• Burris KD, Molski TF, Xu C, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002;302:381-9
   PubMed Web of Science ®Google Scholar
• Kane J, Sanchez R, Perry P, et al. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2012;73:617-24
   PubMed Web of Science ®Google Scholar
• Fleischhacker WW, Sanchez R, Perry PP, et al. Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority study. Br J Psychiatry 2014;205:135-44
   PubMed Web of Science ®Google Scholar
• Mallikaarjun S, Kane JM, Bricmont P, et al. Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: an open-label, parallel-arm, multiple-dose study. Schizophr Res 2013;150:281-8
   PubMed Web of Science ®Google Scholar
• Mallikaarjun S, Salazar DE, Bramer SL. Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers. J Clin Pharmacol 2004;44:179-87
   PubMed Web of Science ®Google Scholar
• Kirschbaum KM, Muller MJ, Malevani J, et al. Serum levels of aripiprazole and dehydroaripiprazole, clinical response and side effects. World J Biol Psychiatry 2008;9:212-18
   PubMed Web of Science ®Google Scholar
• Potkin SG, Raoufinia A, Mallikaarjun S, et al. Safety and tolerability of once monthly aripiprazole treatment initiation in adults with schizophrenia stabilized on selected atypical oral antipsychotics other than aripiprazole. Curr Med Res Opin 2013;29:1241-51
   PubMed Web of Science ®Google Scholar
• Kane JM, Peters-Strickland T, Baker RA, et al. Aripiprazole once-monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2014;75:1254-60
   Google Scholar
• Marder SR, McQuade RD, Stock E, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 2003;61:123-36
   PubMed Web of Science ®Google Scholar
• Kane JM, Zhao C, Johnson B, et al. Hospitalization rates in patients switched from oral antipsychotics to aripiprazole once-monthly: final efficacy analysis. J Med Econ 2014; Epub Nov 10. DOI: 10.3111/13696998.2014.979936
   Google Scholar
• Correll CU. From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics. Eur Psychiatry 2010;25:S12-21
   PubMed Web of Science ®Google Scholar
• Correll CU, Agarwal V, Kane JM. Gradual and Overlapping Antipsychotic Switch Strategies are Associated with Less All-Cause Discontinuation in Schizophrenia: Results from a Meta-Analysis of Different Switch Strategies. Waikoloa, HI, USA: American College of Neuropsychopharmacology, 4–8 December 2011
   Google Scholar
• Correll CU. Real-life switching strategies with second-generation antipsychotics. J Clin Psychiatry 2006;67:160-1
   PubMed Web of Science ®Google Scholar
• Sullivan G, Bienroth M, Jones M, et al. Practical prescribing with aripiprazole in schizophrenia: consensus recommendations of a UK multidisciplinary panel. Curr Med Res Opin 2007;23:1733-44
   PubMed Web of Science ®Google Scholar
• Baker R, Eramo A, Nylander A-G, et al. The effect of previous dose of oral aripiprazole (10 or 30 mg/day) on the efficacy and tolerability of aripiprazole once-monthly: results from post-hoc analyses from two double-blind, randomized, controlled trials. 4th Schizophrenia International Research Society Conference, Florence, Italy, 5–9 April 2014
   Google Scholar
• Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-76
   PubMed Web of Science ®Google Scholar